# Use of PRP to treat plantar fasciitis, blinded and randomized as a multi center study

Published: 11-07-2008 Last updated: 10-08-2024

To compare the efficacy of autologous platelet concentrate injections with corticosteroid injection in patients suffering from plantar fasciitis with respect to pain and function.

**Ethical review** Approved WMO **Status** Recruitment stopped

**Health condition type** Tendon, ligament and cartilage disorders

**Study type** Observational non invasive

## **Summary**

#### ID

NL-OMON32073

#### Source

ToetsingOnline

#### **Brief title**

PRP to treat Plantar fasciitis

#### **Condition**

• Tendon, ligament and cartilage disorders

#### Synonym

plantar fasciitis, policeman's heel

#### Research involving

Human

## **Sponsors and support**

**Primary sponsor:** Sint Elisabeth Ziekenhuis

Source(s) of monetary or material Support: Biomet Nederland BV

#### Intervention

Keyword: blood, plantar fasciitis, platelet gel

#### **Outcome measures**

#### **Primary outcome**

Pain and function measured with questionnaires

#### **Secondary outcome**

nvt

# **Study description**

#### **Background summary**

The standard treatment of chronic plantar fasciitis is corticosteroid injections. Corticosteroid injection give temporarily pain reduction, but no healing. Blood platelets initiate the natural healing rate. GPS ® gives an eightfold concentrate platelets of patients own blood. Injection of these platelets in the tendon might induce a healing rate.

#### **Study objective**

To compare the efficacy of autologous platelet concentrate injections with corticosteroid injection in patients suffering from plantar fasciitis with respect to pain and function.

#### Study design

Randomized, double blinded, multi center trial

#### Study burden and risks

Because autologous blood is used no extra risks are expected as standard for injection in the tendon

## **Contacts**

#### **Public**

**Biomet Nederland BV** 

Hilvarenbeekseweg 60 5000 LC Tilburg NL

#### **Scientific**

Biomet Nederland BV

Hilvarenbeekseweg 60 5000 LC Tilburg NL

## **Trial sites**

#### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### Inclusion criteria

> 18 years

Chronic plantar fasciitis or proximal recalcitrant heel pain (range 3-12 months) Failed conservative treatment

#### **Exclusion criteria**

Received local steroid injections within 6 weeks, physical/occupational therapies within 4 weeks, or non-steroidal anti-inflammatories within 1 week prior ignificant cardiovascular, renal or hepatic disease

Prior surgery for Achilles condition

Pregnant

No informed consent

# Study design

### **Design**

Study phase: 4

Study type: Observational non invasive

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Active

Primary purpose: Treatment

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-11-2008

Enrollment: 120

Type: Actual

## Medical products/devices used

Generic name: Autologous platelet gel

Registration: Yes - CE intended use

Product type: Medicine

Brand name: Corticosteroids

Generic name: triamcinolon acetonide

Registration: Yes - NL intended use

## **Ethics review**

Approved WMO

Date: 11-07-2008

Application type: First submission

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 14-07-2008

Application type: First submission

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 27-01-2009

Application type: Amendment

Review commission: METC Brabant (Tilburg)

Approved WMO

Date: 14-08-2013

Application type: Amendment

Review commission: METC Brabant (Tilburg)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

EudraCT EUCTR2008-001257-18-NL

CCMO NL22305.008.08